(EMAILWIRE.COM, January 06, 2009 ) Dallas- OTCPicks.com’s Daily Small Cap and Microcap Newsletter presents a range of the hottest small cap stocks on trading on the OTC and OTCBB markets. In addition to our Newsletters, OTCPicks.com is quickly becoming the premier community destination for small cap and microcap traders to meet up and discuss their top stock picks. Visit http://www.otcpicks.com/microcap.htm today to join this growing community.

Our Stocks to Watch tomorrow include Veridigm Inc. (OTC: VRGD) and Genta Inc. (OTCBB: GNTA).

Visit http://www.otcpicks.com/microcap.htm to register for our Daily Market Mover's Digest Newsletter, and Email Stock Watch Alerts.

VERIDIGM INCORPORATED (OTC: VRGD)
"Up 131.25% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/VRGD.php

Veridigm is an Anglo American investment company that provides merchant banking services to niche private and specific microcap public companies seeking debt and equity capital and/or to be part of a diversified, equitable, resource sharing, business combination. Specifically, the Company identifies specific private and public companies and assists them with managerial, accounting and financial advice and assists in refinance and / or raise adequate capital by introducing potential investors and lenders. The Company's policy is to calculate its voting capacity on a fully diluted basis. The Company at all times will conduct its activities in such a way that it will not be deemed an "investment company" subject to regulation under the 1940 Act.

GENTA INCORPORATED (OTCBB: GNTA)
"Up 102.70% on Monday"

Detailed Quote: http://www.otcpicks.com/quotes/GNTA.php

Genta Incorporated is a biopharmaceutical company with a diversified product portfolio that is focused on delivering innovative products for the treatment of patients with cancer. Two major programs anchor the Company’s research platform: DNA/RNA-based Medicines and Small Molecules. Genasense® (oblimersen sodium) Injection is the Company's lead compound from its DNA/RNA Medicines program. Genta is currently recruiting patients to the AGENDA Trial, a global Phase 3 trial of Genasense in patients with advanced melanoma. The leading drug in Genta’s Small Molecule program is Ganite® (gallium nitrate injection), which the Company is exclusively marketing in the U.S. for treatment of symptomatic patients with cancer related hypercalcemia that is resistant to hydration. The Company has developed G4544, an oral formulation of the active ingredient in Ganite, that has recently entered clinical trials as a potential treatment for diseases associated with accelerated bone loss. The Company is also developing tesetaxel, a novel, orally absorbed, semi-synthetic taxane that is in the same class of drugs as paclitaxel and docetaxel. Ganite and Genasense are available on a “named-patient” basis in countries outside the United States.

About OTCPicks.com

OTCPicks.com is fast becoming the premier Internet destination for investors seeking information on smallcap and microcap companies. The web site features companies in Profile Campaigns, Executive Interviews and Research Reports authored by our financial writers. We publish our Daily Market Movers Digest Newsletter to opt-in investor members. OTCPicks.com presents the latest information for the discerning small cap and microcap investor. The site features informative articles on microcap investing, the top penny stock picks, and a wealth of small cap research on vertical markets. To feature a company on OTCPicks.com, please contact our publisher, Brian Dean at 972-546-3740, or via email at publisher@otcpicks.com.

Forward-Looking Statement: This press release includes "forward-looking statements" within the meaning of the federal securities laws, commonly identified by such terms as "believes," "looking ahead," "anticipates," "estimates" and other terms with similar meaning. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can give no assurance that these assumptions will prove to be correct. Important factors that could cause actual results to differ materially from the Company's projections and expectations are disclosed in the Company's filings with the Securities and Exchange Commission. All forward-looking statements in this press release are expressly qualified by such cautionary statements and by reference to the underlying assumptions.

Disclosure: OTCPicks.com has not been compensated by any of the companies covered in this release.

OTCPicks.com is not a registered investment advisers or broker/dealer. OTCPicks.com makes no recommendation that the purchase of securities of companies profiled in this website is suitable or advisable for any person or that an investment such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market their securities, investing in such securities is highly speculative and carries a high degree of risk.

Contact Information:
OTCPicks.com
Brian Dean
Tel: 972-546-3740
Email us